Key result
Streptokinase resolves prosthetic valve thrombosis in ~65% of patients, with highest efficacy in double-disk valves.
Why the study?
Does fibrinolytic therapy with streptokinase resolve thrombosis and improve clinical and hemodynamic outcomes in hemodynamically stable, high-surgical-risk patients with cardiac valvular prosthesis thrombosis?
Cohort (n=17)
No
Does fibrinolytic therapy with streptokinase resolve thrombosis and improve clinical and hemodynamic outcomes in hemodynamically stable, high-surgical-risk patients with cardiac valvular prosthesis thrombosis?
Fibrinolytic therapy with streptokinase is an effective alternative to surgery for patients with primary thrombosis of double-disk mechanical cardiac valve prostheses, though it carries notable risks of embolism (17.6%), fatal hemorrhage (5.8%), and late rethrombosis (33%).
Answers are grounded in this paper and cite their sources.
Streptokinase may be considered in high-surgical-risk prosthetic valve thrombosis; leaves open the need for randomized trials to confirm safety and durability.
OBJECTIVE: To assess the short- and long-term results of the use of streptokinase (SK) for the treatment of thromboses in cardiac valvular prostheses. METHODS: Seventeen patients with cardiac prosthetic thrombosis diagnosed by clinical, echocardiographic, and radioscopic findings underwent fibrinolytic treatment with a streptokinase bolus of 250,000 U followed by 100.000 U/hour. Short- and long-term results were assessed by radioscopy and echocardiography. RESULTS: Of the 17 patients, 12 had mechanical double-disk prostheses (4 aortic, 6 mitral, 2 tricuspid), 4 had single-disk prostheses (2 aortic, 1 mitral, and 1 tricuspid), and 1 had a tricuspid bioprosthesis. The success rate was 64.8%, the partial success rate was 17.6%, and the nonsuccess rate was 17.6%. All patients with a double-disk prosthesis responded, completely or partially, to the treatment. None of the patients with a single-disk prosthesis had complete resolution of the thrombosis. The time of streptokinase infusion ranged from 6 to 80 hours (mean of 56 h). The mortality rate due to the use of streptokinase was 5.8% and was secondary to cerebral bleeding. During streptokinase infusion, 3 (17.6%) embolic episodes occurred as follows: 1 cerebral, 1 peripheral, and 1 coronary. The rethrombosis index was 33% in a mean follow-up of 42 months. CONCLUSION: The use of fibrinolytic agents was effective and relatively safe in patients with primary thrombosis of a double-disk prosthesis. A fatal hemorrhagic complication occurred in 1 (5.8%) patient, and embolic complications occurred in 3 (17.6%) patients. In a mean 42-month follow-up, 67% of the patients were free from rethrombosis.
No takes yet. Share an insight, caveat, or question.
Ramos et al. (2003) conducted a cohort in Cardiac valvular prosthesis thrombosis (n=17). Streptokinase was evaluated on Complete resolution of prosthetic thrombosis (improvement in clinical findings, normalization of disk mobility on fluoroscopy, and reduction in transprosthetic gradient). Streptokinase therapy achieved a 64.8% complete success rate and 17.6% partial success rate in resolving cardiac valvular prosthesis thrombosis, with all double-disk prostheses responding.
Synapse has enriched 10 related papers. Consider them for comparative context: